Summary of effectiveness and impact of rotavirus vaccination with the oral pentavalent rotavirus vaccine: A systematic review of the experience in industrialized countries

@article{Giaquinto2011SummaryOE,
  title={Summary of effectiveness and impact of rotavirus vaccination with the oral pentavalent rotavirus vaccine: A systematic review of the experience in industrialized countries},
  author={Carlo Giaquinto and G{\'e}raldine Dominiak-Felden and Pierre van Damme and Tin Tin Htar Myint and Yvonne Maldonado and Vana Spoulou and Thomas Christopher Mast and Mary A Staat},
  journal={Human Vaccines},
  year={2011},
  volume={7},
  pages={734 - 748}
}
The pentavalent rotavirus (RV) vaccine RotaTeq™ has been available in industrialized countries since 2006. Several studies have been conducted to evaluate the benefit of RV vaccination under routine conditions of use. A systematic review of all publicly available data from RotaTeq™ vaccine-effectiveness and vaccination-impact studies in the USA, Europe and Australia between 2006 and February 2010 was undertaken. Depending on the population studied, effectiveness of up to 100% (95% confidence… Expand
Impact and Effectiveness of RotaTeq® Vaccine Based on 3 Years of Surveillance Following Introduction of a Rotavirus Immunization Program in Finland
TLDR
Severe RVGE requiring hospitalization was virtually eliminated in vaccine-eligible children in the 3 years following implementation of universal RotaTeq vaccination in Finland. Expand
Effectiveness and impact of rotavirus vaccines in Europe, 2006-2014.
TLDR
Across Europe, vaccine effectiveness against rotavirus-related healthcare utilisation ranged from 68% to 98%, consistent with efficacy data from clinical trials and with findings from post-marketing studies from the US and Latin America. Expand
Rotavirus vaccines: a story of success.
TLDR
Data now strongly suggest that even if there might be a relative increase of some specific genotypes after the use of rotavirus vaccines, this is not an absolute increase in incidence from certain genotypes and does not affect the overall effectiveness of rotovirus mass vaccination, which resulted in a major decrease of severe cases of rotvirus gastroenteritis in both industrialized and resource deprived countries. Expand
The cost-effectiveness of pentavalent rotavirus vaccination in England and Wales.
TLDR
The results indicate that rotav virus vaccination would be beneficial to public health and could be economically sound and inform policymakers of the cost-effectiveness and budget impact of implementing a mass rotavirus vaccine strategy. Expand
The cost effectiveness of rotavirus vaccination in Iran
TLDR
Introducing rotavirus vaccine into EPI program would be highly cost-effective public health intervention in Iran and a saving for the society with the same averted DALYs. Expand
Nosocomial rotavirus infection: An up to date evaluation of European studies
TLDR
The aim of this review is to summarize the epidemiology of both CARV and nRV in order to discuss the difficulty of a clear evaluation of the burden of the disease in absence of comparable data. Expand
Economic assessment of rotavirus vaccination in Saudi Arabia.
TLDR
Rotavirus vaccination should be recommended in KSA given the important clinical impact the vaccine can have and the good value for money it can obtain. Expand
Effectiveness of rotavirus vaccines in an Australian population: A case-control study.
TLDR
RV1 and RV5 were both effective in preventing laboratory confirmed and notified rotavirus infections among children aged <5 years, and even incomplete courses of vaccination conferred good protection. Expand
Primary care-based surveillance to estimate the proportion of rotavirus gastroenteritis among Latvian children below 5 years of age with acute gastroenteritis
TLDR
It is underlines that RV is an important cause of AGE in children under 5 years old in Latvia and that the burden of disease of RVGE in primary care was substantial before inclusion of RV vaccination in the NIP. Expand
Major reduction of rotavirus, but not norovirus, gastroenteritis in children seen in hospital after the introduction of RotaTeq vaccine into the National Immunization Programme in Finland
TLDR
RV vaccination in NIP has led to a major reduction of hospital admissions and clinic visits due to RVGE, but has had no effect on NVGE, which has become the leading cause of acute GE in children seen in hospital. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 83 REFERENCES
Effectiveness of the Pentavalent Rotavirus Vaccine in Preventing Gastroenteritis in the United States
TLDR
In this first nationwide study evaluating VE under conditions of routine use, RV5 was highly effective in preventing RGE and AGE and in reducing health care resource utilization. Expand
RotaTeq™: a three-dose oral pentavalent reassortant rotavirus vaccine
TLDR
Results from a large clinical trial, as well as ongoing postmarketing surveillance, indicate that the 3-dose oral pentavalent RV vaccine (RotaTeq™) is safe and well tolerated, without evidence of increased risk of intussusception. Expand
RotaTeq, a pentavalent rotavirus vaccine: efficacy and safety among infants in Europe.
TLDR
A pentavalent human-bovine reassortant oral rotavirus vaccine, RotaTeq, was evaluated among nearly 70,000 infants in the Rotavirus Efficacy and Safety Trial (REST), of which 30,523 were from Europe and was highly efficacious and well tolerated. Expand
Uptake, Impact, and Effectiveness of Rotavirus Vaccination in the United States: Review of the First 3 Years of Postlicensure Data
TLDR
The implementation of routine childhood immunization againstRotavirus has rapidly and dramatically reduced the large health burden of rotavirus gastroenteritis in US children and continued monitoring of rotvirus diarrhea is needed to determine if immunity wanes as vaccinated children get older and to better quantify the indirect benefits of vaccination. Expand
Decline in Cases of Rotavirus Gastroenteritis Presenting to The Children's Hospital of Philadelphia after Introduction of a Pentavalent Rotavirus Vaccine
TLDR
The abrupt decline in rotavirus gastroenteritis cases during the 2007-2008 season likely resulted from vaccination, and protection rates appeared to have exceeded vaccination rates, so herd immunity may have contributed to some degree to the effectiveness of the vaccine. Expand
Reduction in Rotavirus-associated Acute Gastroenteritis Following Introduction of Rotavirus Vaccine Into Australia's National Childhood Vaccine Schedule
TLDR
Early evidence from the NIP in Australia has demonstrated high rotavirus coverage with both RV1 and RV5, supportive of both direct vaccine protection, as well as with indirect herd protection. Expand
Pentavalent Rotavirus Vaccine and Prevention of Gastroenteritis Hospitalizations in Australia
TLDR
RV5 is highly effective at preventing rotavirus hospitalizations in a developed country setting, confirming efficacy figures from the pivotal clinical trial. Expand
Rotavirus Vaccines in Belgium: Policy and Impact
TLDR
A decrease in the number of rotavirus infections and a 4- to 6-week delay in the onset of disease and the peak of incidence in the postvaccination period coincides with the increased vaccine uptake. Expand
Rotavirus Hospital Surveillance in the Era of Immunization
TLDR
In New Orleans, G3P(8) is becoming a predominant strain of RV, and it is unclear whether this phenomenon represents natural variation or it is caused by introduction of vaccines. Expand
Cost-effectiveness and Potential Impact of Rotavirus Vaccination in the United States
TLDR
Routine rotavirus vaccination would unlikely be cost-saving in the United States at present, but may still be considered a cost-effective intervention. Expand
...
1
2
3
4
5
...